about
Role of lipotoxicity in endothelial dysfunctionPrevalence and determinants of diabetic nephropathy in Korea: Korea national health and nutrition examination survey.Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients.Association of dyslipidemia with renal outcomes in chronic kidney disease.Dyslipidemia associated with chronic kidney diseaseAssociation between high-density lipoprotein cholesterol and renal function in elderly hypertension: a cross-sectional study in Chinese population.Effects of Oral L-Carnitine Supplementation on Lipid Profile, Anemia, and Quality of Life in Chronic Renal Disease Patients under Hemodialysis: A Randomized, Double-Blinded, Placebo-Controlled TrialLipid abnormalities, lipoprotein (a) and apoprotein pattern in non-dialyzed patients with chronic kidney diseaseEffect of Genistein and L-Carnitine and Their Combination on Gene Expression of Hepatocyte HMG-COA Reductase and LDL Receptor in Experimental Nephrotic Syndrome.Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.Kidney Function as a Determinant of HDL and Triglyceride Concentrations in the Australian Population.Role of HDL dysfunction in end-stage renal disease: a double-edged sword.Systemic and renal lipids in kidney disease development and progression.iTRAQ-based proteomic analysis of plasma reveals abnormalities in lipid metabolism proteins in chronic kidney disease-related atherosclerosis.A Comparative Study of Lipid Profile and Cardiovascular Risk Biomarkers Among Chronic Haemodialysis Patients and Healthy Individuals.Interruption of antiretroviral therapy is associated with increased plasma cystatin CCauses of dysregulation of lipid metabolism in chronic renal failure.Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.Statins in patients with chronic kidney disease: why, who and when?High-density lipoprotein in uremic patients: metabolism, impairment, and therapy.Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients.Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences.PCSK9 in chronic kidney disease.Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.Dyslipidaemia in patients with lupus nephritis.Diet and enteral nutrition in patients with chronic kidney disease not on dialysis: a review focusing on fat, fiber and protein intake.Dyslipidemia and risk of renal replacement therapy or death in incident pre-dialysis patients.Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease.Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation.Effect of Genistein and L-carnitine and Their Combination on Lipid Profile and Inflammatory Cytokines in Experimental Nephrotic Syndrome
P2860
Q27000731-EF96C1F8-FEC2-4137-89FD-78AEB296425FQ33612502-A13F0293-2AC3-48B0-8861-FAF0B7BED8FCQ33932598-167FF860-2667-4A0D-A212-1D8551EC7FAEQ34580123-4F35DE40-8AEE-471E-BC19-4A4134B0C1DEQ35020237-ABF32C46-5D35-4EC1-ADA0-B13E430D70EDQ36009267-2D03AD08-E1C7-48E6-8AE5-337EB00F07ECQ36031155-508763D5-D7C9-4B35-AAEF-D0C13C86EE07Q36262864-7670C76B-51A6-4107-8D10-0DAEE1F9F232Q36279251-9163CCB4-EA73-49E8-9916-52C4CB18F6A9Q36721867-C09A1C72-CF13-496F-BAA8-2BA8604B93F6Q36735361-041791A4-489C-435A-BB30-173742AA39C6Q36876162-6DD8E910-EE24-4C57-B03C-993DA0A0D905Q37148885-AF1E4CD3-AB86-4E41-B252-76CC04204888Q37236242-F7CD6431-7F42-4F5E-AB3B-C1AED3B4DCF7Q37353053-11AE6DF9-C4AD-4F30-B2EB-9DCF52D971E0Q37386153-27D2F26A-D659-42B7-81D1-F6BE1EB318DCQ37657707-3F2CFA40-7676-468F-9DCC-3617D0F17FD2Q37775007-DB95068C-FE6B-4831-AD6B-FC2B0299CCC4Q37803236-4D5AAAB4-01AD-4450-88CB-C7266F9D8B70Q38084913-E4438CFC-9A98-477C-B4D1-C1DA1637C4A6Q38131300-114E649F-198D-40A6-A7D5-C033B850F4F4Q38758014-13FDCDCC-AD3F-4B8E-B995-91E2B29EB9DEQ38831462-0697D88F-0285-4200-A447-CC786EE43712Q39022581-6330D2BC-F97A-48FF-969F-59986E86FF72Q43247391-842C7EBE-E2E2-45A9-B5FC-706654C809A7Q44220064-93F41AD8-FF2A-45FB-A5CE-AE7A4003E98FQ47836803-EE7F4FD2-5F43-4714-AF6B-5D78DE8100DCQ49959013-EF4069C1-4C6F-4207-A1D7-D4EB811CA051Q51629961-BA771E60-6C91-4FE2-BA6D-B90E49E93585Q52650772-60E5E5B1-D9CB-44E5-A9AB-C0B47A34581DQ57489070-9B856D4B-4615-406D-8CF8-7ED9CC30A522
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Mechanisms of dyslipidemia of chronic renal failure.
@ast
Mechanisms of dyslipidemia of chronic renal failure.
@en
type
label
Mechanisms of dyslipidemia of chronic renal failure.
@ast
Mechanisms of dyslipidemia of chronic renal failure.
@en
prefLabel
Mechanisms of dyslipidemia of chronic renal failure.
@ast
Mechanisms of dyslipidemia of chronic renal failure.
@en
P2860
P1476
Mechanisms of dyslipidemia of chronic renal failure.
@en
P2093
Hamid Moradi
Nosratola D Vaziri
P2860
P356
10.1111/J.1542-4758.2006.01168.X
P577
2006-01-01T00:00:00Z